Specialist in the field of adaptive immunity, co-author of more than 170 papers in peer-reviewed scientific journals, a number of international patents. Hirsch index - 74, citations - 24,000. Participated in more than 50 international conferences. Developed the first-in-class drug for targeted therapy of an autoimmune disease – Ankylosing spondylitis, based on a monoclonal antibody to the segment of the T-cell receptor TRBV9. The drug Tribuvia (Seniprutug) has passed clinical trials and is approved for use, manufactured by Biocad. Developed molecular methods and data analysis algorithms for studying the repertoires of adaptive immunity receptors: T-cell receptors and antibodies. Researched fundamental patterns of development and organization of adaptive immunity in health and disease, patterns of aging of adaptive immunity. Researched various aspects of application of T-cell receptor and antibody repertoire analysis in medical practice, molecular mechanisms of development of autoimmune diseases, interactions between tumors and the immune system. Developed a palette of fluorescent proteins and a number of methods for their application in biomedical research, widely used today in scientific laboratories and pharmaceutical companies around the world, described the mechanism of reversible photoactivation of fluorescent proteins.